Implications of COVID-19 on impairment testing under IAS36
COVID-19 has developed rapidly, impacting equity markets with high volatility as our real economy is set for an unprecedented decline. As such, COVID-19 could represent a trigger for impairment testing for companies.
During this virtual session, we provide in-depth understanding of the need for performing a trigger-based impairment test. We focus on the impact of the crisis on key input parameters, scenario analysis, discount rates, and the terminal value. Disclosure requirements naturally are an integral part of the webinar.
John Peters, Frank de Lange and Prof. dr. Arjan Brouwer RA, partner and Chief Accountant of PwC The Netherlands, will share their knowledge during this webinar.
How do you ensure that you pay, or receive, the right price when buying or selling a company or business unit? Important strategic decisions such as these cannot be based on approximate calculations and figures. You need a proper valuation. One based on facts that provides insight and is borne out in negotiations. One that can withstand the test of critical appraisal by stakeholders.
Our approach is characterised by our independence and objectivity. This is very much to our advantage, because it means that your stakeholders can rely on our valuations. Our highly experienced specialists possess in-depth knowledge of your sector and will conduct a purposeful and thorough valuation, being suitably pragmatic and not getting bogged down in detail. This will give you a clear understanding of the value, and the factors that determine the value, so you can make well-informed decisions.
We can give you a clear valuation, whether you need it for:
© 2015 - Sun Apr 11 15:37:01 UTC 2021 PwC. PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.